2022 RBC Capital Markets Global Healthcare Conference

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome

Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants

Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference

Oak Hill Bio Joins C-Path’s International Neonatal Consortium

Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium

Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology

Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference

Oak Hill Bio Launches with Pipeline and Senior Leadership from Takeda